{"title": "PDF", "author": "PDF", "url": "https://imperialbrc.nihr.ac.uk/wp-content/uploads/2022/02/Initiation-Q2-2020-21.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "REC Ref No. IRAS No. Name of Trial Date First Participant RecruitedDate Site InvitedDate Site SelectedHRA Approval DateDate Site Confirmed By SponsorDate Site ConfirmedNon- Confirmation StatusDate Site Ready To correspond to: 20/LO/1106 Phase 1b, of Tilvestamab (BGB149) in 23/09/2020 A Long-term Follow-up Study of Subjects With \u00ce\u00b2-thalassemia or Sickle Cell Disease Treated with Autologous group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following surfactant therapy versus expectant management in late preterm and early term infants with respiratory distress.14/07/2020 Sponsor 20/LO/0745 273024 Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations c-Met Dysregulation Advanced Neither 20/EE/0204 287569 A PHASE II, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE PHARMACODYNAMIC EFFECTS OF ONCE WEEKLY ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER\u00e2\u20acS DISEASE24/08/2020 20/HRA/3414 284196 Investigating between DIRECT Solitaire\u00e2\u00a2 Stroke08/04/2020 Neither 20/EM/0115 A randomised phase II proof of principle multi-arm multi- stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with 279315 safety and immunogenicity of a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein cancers06/04/2020 29/07/2020 20/EM/0036 278520 A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia.24/03/2020 06/07/2020 Three Parallel-Arm Study of PF-06801591, an anti-PD-1 antibody, in Combination with Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK- 7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after study evaluate the long-term efficacy, safety and tolerability of LNP023 in the LOIS Smartband in patients undergoing elective ICD Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome01/05/2020 01/05/2020 29/05/2020 21/05/2020 29/05/2020 Neither World Hip Trauma Evaluation 9\u00cd\u00be Blood Cell Salvage Trial. A multi centre randomised controlled trial comparing intra operative cell salvage with standard care in the treatment of hip fractures.23/04/2020 31/08/2020 02/09/201920/EE/0118 283014 A phase III prospective, interventional, cohort, superiority study to evaluate the benefit of rapid COVID-19 genomic sequencing (the COVID-19 GENOMICS UK project) on infection control in preventing the spread of the virus in United Kingdom NHS hospitals23/04/2020 21/09/2020 20/EM/0087 5- fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of to evaluate the safety and efficacy of tocilizumab in patients with Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734\u00e2\u00a2) in Participants with Moderate COVID-19 Compared to Treatment10/04/2020 27/03/2020 controlled study to evaluate the efficacy, safety, and tolerability of Rozanolixizumab in adult study participants with persistent or chronic primary immune thrombocytopenia (ITP)- TP000320/03/2020 25/03/2020 Neither 20/NE/0104 282007 A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734\u00e2\u00a2) in 20/LO/0574 281827 Preventing Cardiac Complications of COVID-19 Disease with Early Acute Coronary Syndrome Therapy: Superficial Wound Drain on Surgical Site Infection in high Body Mass Index (BMI) Kidney Transplants Recipients.02/07/2020 05/08/2020 20/SC/0116 272955 Brain connectivity and patient reported outcomes in people with HIV with symptoms of insomnia switching integrase inhibitor-based Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Pamrevlumab or Placebo in combination with Gemcitabine Plus Nabpaclitaxel as Neoadjuvant Treatment in Patients Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 (aducanumab) in Subjects with Alzheimer\u00e2\u20acs disease Who Had Previously Participated in the Aducanumab study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of a continuous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms in Kawasaki disease20/02/2020 Double-Blind, Randomised, Controlled 48- week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer\u00e2\u20acs Disease Centre Trial of Conservative versus Liberal Oxygenation Targets in Critically Ill Children28/01/2020 28/01/2020 23/12/2019 02/10/2020 Sponsor 275910 A Physiological Study of the Effect of \u00ce'lpha-MSH Healthy Participants25/08/2020 10/09/2020 randomised trial of heme arginate versus placebo to reduce delayed graft function in kidney transplant recipients22/01/2020 23/01/2020 Neither 20/YH/0090 278137 AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF LONG- TERM ADMINISTRATION OF GANTENERUMAB Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment gonorrhoeae22/01/2020 11/02/2020 HDAC6 inhibition with KA2507 in advanced biliary tract cancer previously treated with standard of care chemotherapy to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute Double-Blind, Placebo-Controlled 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic 18/WM/0275 211232 A prospective non-randomised multi-centre feasibility study to assess if patients with residual cancer following dual- targeted neoadjuvant chemotherapy treatment for HER2- positive, ER-negative early breast cancer can be identified by multiple ultrasound (US)-guided tumour bed core 10/03/2020 Neither 19/EE/0326 270902 A randomised double-blind placebo controlled phase 3 trial to evaluate the efficacy and safety of estetrol for the treatment of moderate to severe vasomotor symptoms in postmenopausal women Twin-Twin Transfusion Syndrome (USgHIFU-TTTS)03/12/2019 09/03/2020 Sponsor 19/YH/0351 270898 A phase 2, prospective, randomised, double-blind, placebo- controlled clinical study to assess the efficacy, safety, tolerability, and pharmacokinetics of SJX-653 in postmenopausal controlled, Phase 2a study to evaluate the safety and efficacy of administering Regadenoson to patients with critical injury and signs of haemorrhagic randomized, open label two arm study comparing the effect of crizanilumab + standard of care alone on renal function in sickle cell disease patients \u00e2\u00a5 16 years with chronic kidney disease due to sickle nephropathy18/09/2019 18/12/2019 06/12/2019 03/02/2020 04/02/2020 association between arterial spectral waveforms feature or flow profiles and arteriovenous fistula to the \u00e2\u20acbest in 04/08/2020 19/LO/1583 271866 A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients OF MTL-CEBPA IN COMBINATION WITH A PD-1 INHIBITOR (PEMBROLIZUMAB) IN of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Evaluation of a single use point of care device for the diagnosis of influenza and other respiratory pathogens in clinical upper airway samples using to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX- SPL9111 (a prospective international EKoSoNic\u00c2\u00ae registry Of the treatment and Clinical OUTcomes of patients Pulmonary Embolism12/02/2020 06/06/2019 safety, toleraribility pharmacokinetics, and Anti-tumor activity of TPX-0005 in PAtients with Advanced Solid Tumors study evaluating point of care gastric lipase enhanced pH test strip to confirm correct nasogastric tube in and polycystic ovarian syndrome related Placebo- Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the 11/11/2019 Sponsor 19/ES/0136 270742 A Randomized, to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, (PMF), Vera (PV) Myelofibrosis, or Post Essential Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy in Subjects with DIPPS-Intermediate or High-risk Primary Myelofibrosis, Post-Polycythemia Vera Randomised Clinical Trial of Therapeutic Interventions with the Potential to Improve Outcome in Adults with Acute Myeloid Leukaemia and High Risk Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to patients with antiphospholipid syndrome, with or without SLE (RISAPS): a STING Agonist E7766 in Subjects Advanced Sponsor 19/LO/1669 266322 The RIO controlled trial of dual long- acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART-only in treated primary HIV infection - A two-stage randomised phase II placebo controlled clinical trial14/01/2020 19/LO/0943 264067 (MK-3475) + versus Perioperative Placebo + Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction after trial17/04/2019 15/10/2019 Neither 19/LO/1290 262104 Non-Invasive Continuous Cardiac Continuous Glucose Monitoring on Glycaemic Control in High-risk Adolescents and Young Adults with Insulin-treated Preterm a ruCaparib combined with Nivolumab +/- Ipilimumab to augment response in homologous repair deficient patients with relapsed Ovarian, primary peritoneal and fallopian tube cancer06/02/2019 26/02/2020 14/05/2019 and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who of Dexcom G6 real-time continuous glucose monitoring with a predictive hypoglycaemia alert function on the frequency, duration and severity of hypoglycaemia occurring before, during and after regular physical activity in people with type 1 evaluate the safety, tolerability, and effects of Livoletide (AZP-531), an unacylated ghrelin 19/LO/0063 255904 the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION24/04/2020 01/06/2020 Neither 19/LO/0062 255909 A study evaluating the efficacy and safety of ralinepag to improve treatment outcomes in PAH cardioplegia on biomarkers of organ injury in patients having cardiac surgery using cardiopulmonary bypass: Propofol cardioplegia prospective study to assess the efficacy and safety of the BlueWind RENOVA iStim\u00e2\u00a2 system for the treatment of patients overactive bladder18/07/2018 30/10/2019 Sponsor 17/EM/0440 230556 A randomised phase to evaluate the Duration of ANti- PD1 monoclonal antibody Phase 2, Multicenter, Double- Blinded, Sham-Procedure Controlled Trial of Renal Denervation by the Peregrine System\u00e2\u00a2 Kit , 03/08/2016 02/03/2020 16/07/2020 30/07/2020 Sponsor "}